THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING
A trial fibrillation occurs in 5 to 8% of patients who underwent percutaneous coronary intervention (PCI) with stenting. It is known that dual antiplatelet therapy (a combination of P2Y12 receptor inhibitor and acetylsalicylic acid) significantly reduces the risk of developing stent thrombosis in co...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2017-05-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/114 |
| _version_ | 1797883925153972224 |
|---|---|
| author | N. A. Novikova A. S. Shilova |
| author_facet | N. A. Novikova A. S. Shilova |
| author_sort | N. A. Novikova |
| collection | DOAJ |
| description | A trial fibrillation occurs in 5 to 8% of patients who underwent percutaneous coronary intervention (PCI) with stenting. It is known that dual antiplatelet therapy (a combination of P2Y12 receptor inhibitor and acetylsalicylic acid) significantly reduces the risk of developing stent thrombosis in comparison with vitamin K antagonists; however, anticoagulants are significantly more effective in reducing the risk of ischemic stroke in patients with atrial fibrillation (AF). When opting for a long-term triple antithrombotic therapy, the risk of hemorrhagic complications increases dramatically, while choosing less intensive treatment results in an increased risk of ischemic complications, primarily, ischemic stroke and stent thrombosis. The current recommendations come down to the prescription of all of the three components of antithrombotic therapy. However, this approach leads to a significant increase in the frequency of hemorrhagic complications. The purpose of recent randomized trials was to compare and evaluate the efficacy and safety of different regimens with antithrombotic drugs in combination with rivaroxaban in patients with AF who underwent PCI. |
| first_indexed | 2024-04-10T03:59:33Z |
| format | Article |
| id | doaj.art-7c6771cd07894b33a59a7fa138a9f8e5 |
| institution | Directory Open Access Journal |
| issn | 2307-1109 2658-5952 |
| language | Russian |
| last_indexed | 2024-04-10T03:59:33Z |
| publishDate | 2017-05-01 |
| publisher | «REMEDIUM GROUP» Ltd. |
| record_format | Article |
| series | Атеротромбоз |
| spelling | doaj.art-7c6771cd07894b33a59a7fa138a9f8e52023-03-13T07:10:42Zrus«REMEDIUM GROUP» Ltd.Атеротромбоз2307-11092658-59522017-05-010111412110.21518/2307-1109-2017-1-114-121108THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTINGN. A. Novikova0A. S. Shilova1Первый Московский государственный медицинский университет им. И.М. СеченоваПервый Московский государственный медицинский университет им. И.М. СеченоваA trial fibrillation occurs in 5 to 8% of patients who underwent percutaneous coronary intervention (PCI) with stenting. It is known that dual antiplatelet therapy (a combination of P2Y12 receptor inhibitor and acetylsalicylic acid) significantly reduces the risk of developing stent thrombosis in comparison with vitamin K antagonists; however, anticoagulants are significantly more effective in reducing the risk of ischemic stroke in patients with atrial fibrillation (AF). When opting for a long-term triple antithrombotic therapy, the risk of hemorrhagic complications increases dramatically, while choosing less intensive treatment results in an increased risk of ischemic complications, primarily, ischemic stroke and stent thrombosis. The current recommendations come down to the prescription of all of the three components of antithrombotic therapy. However, this approach leads to a significant increase in the frequency of hemorrhagic complications. The purpose of recent randomized trials was to compare and evaluate the efficacy and safety of different regimens with antithrombotic drugs in combination with rivaroxaban in patients with AF who underwent PCI.https://www.aterotromboz.ru/jour/article/view/114ривароксабантройная антитромботическая терапияфибрилляция предсердийчрескожное вмешательство на коронарных артерияхгеморрагические осложнения |
| spellingShingle | N. A. Novikova A. S. Shilova THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING Атеротромбоз ривароксабан тройная антитромботическая терапия фибрилляция предсердий чрескожное вмешательство на коронарных артериях геморрагические осложнения |
| title | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_full | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_fullStr | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_full_unstemmed | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_short | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_sort | specifics of prescribing triple antitrombotic therapy with rivaroxaban in patients with atrial fibrillation after coronary artery stenting |
| topic | ривароксабан тройная антитромботическая терапия фибрилляция предсердий чрескожное вмешательство на коронарных артериях геморрагические осложнения |
| url | https://www.aterotromboz.ru/jour/article/view/114 |
| work_keys_str_mv | AT nanovikova thespecificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting AT asshilova thespecificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting AT nanovikova specificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting AT asshilova specificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting |